Inventor · disambiguated record
Stephen J. Haggarty
Also filed as: HAGGARTY STEPHEN · HAGGARTY STEPHEN J · HAGGARTY STEPHEN JOHN
32 granted patents·23 pending applications·212 citations·filing 2003–2024
97Inventor score
Files withBROAD INST INC9TSAI LI-HUEI9MASSACHUSETTS INST TECHNOLOGY8MASSACHUSETTS GEN HOSPITAL7DANA FARBER CANCER INST INC5
Top patents by PatentIndex Score
55 records- 0195US7244853B2Dioxanes and uses thereofHARVARD COLLEGE·Filed 2003·Granted Jul 17, 2007·69 cites·54 claims
- 0293US10662199B2Inhibitors of histone deacetylaseBROAD INST INC·Filed 2017·Granted May 26, 2020·3 cites·39 claims
- 0393US9988343B2Inhibitors of histone deacetylaseDANA FARBER CANCER INST INC·Filed 2014·Granted Jun 5, 2018·7 cites·22 claims
- 0492US9890172B2Inhibitors of histone deacetylaseBROAD INST INC·Filed 2016·Granted Feb 13, 2018·10 cites·28 claims
- 0591US9447030B2Inhibitors of histone deacetylaseBROAD INST INC·Filed 2013·Granted Sep 20, 2016·13 cites·22 claims
- 0691US9365498B2Inhibitors of histone deacetylaseBROAD INST INC·Filed 2013·Granted Jun 14, 2016·13 cites·22 claims
- 0791US8178579B2Dioxanes and uses thereofSCHREIBER STUART L·Filed 2007·Granted May 15, 2012·13 cites·55 claims
- 0891US8088951B2Epigenetic mechanisms re-establish access to long-term memory after neuronal lossTSAI LI-HUEI·Filed 2007·Granted Jan 3, 2012·10 cites·15 claims
- 0990US8999289B2Treatment of protein degradation disordersANDERSON KENNETH C·Filed 2006·Granted Apr 7, 2015·16 cites·32 claims
- 1088US10137122B2Kinase inhibitors and methods of use thereofBROAD INST INC·Filed 2015·Granted Nov 27, 2018·8 cites·66 claims
- 1187US9572854B2Treatment of protein degradation disordersHARVARD COLLEGE·Filed 2015·Granted Feb 21, 2017·6 cites·20 claims
- 1287US9096594B2Kinase inhibitors and methods of use thereofBROAD INST INC·Filed 2013·Granted Aug 4, 2015·9 cites·22 claims
- 1383US11052080B2Kinase inhibitors and methods of use thereofBROAD INST INC·Filed 2018·Granted Jul 6, 2021·3 cites·31 claims
- 1483US10828367B2Photoswitchable HDAC inhibitorsMASSACHUSETTS GEN HOSPITAL·Filed 2018·Granted Nov 10, 2020·1 cites·16 claims
- 1583US10172905B1Treatment of protein degradation disordersHARVARD COLLEGE·Filed 2017·Granted Jan 8, 2019·3 cites·20 claims
- 1683US8263547B2DISC-1 pathway activators in the control of neurogenesisTSAI LI-HUEI·Filed 2009·Granted Sep 11, 2012·9 cites·9 claims
- 1781US11572368B2Inhibitors of histone deacetylaseMASSACHUSETTS GEN HOSPITAL·Filed 2016·Granted Feb 7, 2023·1 cites·38 claims
- 1881US9790184B2Inhibitors of histone deacetylaseMASSACHUSETTS GEN HOSPITAL·Filed 2013·Granted Oct 17, 2017·6 cites·25 claims
- 1976US11377423B2Inhibitors of histone deacetylaseBROAD INST INC·Filed 2017·Granted Jul 5, 2022·2 cites·91 claims
- 2074US9981038B2Photoswitchable HDAC inhibitorsMASSACHUSETTS GEN HOSPITAL·Filed 2014·Granted May 29, 2018·2 cites·13 claims
- 2173US9115053B2Activators of class I histone deacetlyases (HDACS) and uses thereofTSAI LI-HUEI·Filed 2012·Granted Aug 25, 2015·2 cites·12 claims
- 2272US12419885B2Kinase inhibitors and methods of use thereofBROAD INST INC·Filed 2021·Granted Sep 23, 2025·0 cites·42 claims
- 2372US11596691B2Photoswitchable HDAC inhibitorsMASSACHUSETTS GEN HOSPITAL·Filed 2020·Granted Mar 7, 2023·0 cites·3 claims
- 2472US9265764B2Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disordersHAGGARTY STEPHEN J·Filed 2010·Granted Feb 23, 2016·3 cites·18 claims
- 2571US2022064151A1Activators of class i histone deacetylases (hdacs) and uses thereofMASSACHUSETTS INST TECHNOLOGY·Filed 2021·Application pending·0 cites
- 2670US10167277B2Activators of class I histone deacetlyases (HDACs) and uses thereofMASSACHUSETTS INST TECHNOLOGY·Filed 2015·Granted Jan 1, 2019·1 cites·27 claims
- 2770US10124035B2DISC-1 pathway activators in the control of neurogenesisTSAI LI HUEI·Filed 2012·Granted Nov 13, 2018·2 cites·3 claims
- 2869US2024091213A1Compounds for tau protein degradationDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 2968US2025090504A1Small molecule peptidomimetic for the treatment of tauopathiesSTEALTH BIOTHERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3065US11639325B2Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disordersMASSACHUSETTS INST TECHNOLOGY·Filed 2020·Granted May 2, 2023·0 cites·42 claims
- 3165US11180438B2Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disordersMASSACHUSETTS INST TECHNOLOGY·Filed 2018·Granted Nov 23, 2021·0 cites·21 claims
- 3265US11084803B2Activators of class I histone deacetylases (HDACs) and uses thereofMASSACHUSETTS INST TECHNOLOGY·Filed 2018·Granted Aug 10, 2021·0 cites·25 claims
- 3363USRE49240EInhibitors of histone deacetylaseMASSACHUSETTS GEN HOSPITAL·Filed 2014·Granted Oct 11, 2022·0 cites·22 claims
- 3463US2012046242A1Molecular activators of the wnt/beta-catenin pathwayMOON RANDALL T·Filed 2009·Application pending·0 cites
- 3560US2010075926A1Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survivalTSAI LI-HUEI·Filed 2009·Application pending·0 cites
- 3658US2021154184A1Compounds for tau protein degradationDANA FARBER CANCER INST INC·Filed 2018·Application pending·0 cites
- 3755US2023227852A1Arrdc1-mediated microvesicle-based delivery to the nervous systemHARVARD COLLEGE·Filed 2021·Application pending·0 cites
- 3855US2012040916A1Molecular inhibitors of the wnt/beta-catenin pathwayMOON RANDALL T·Filed 2009·Application pending·0 cites
- 3955US2024366594A1Small Molecule Inhibitors of Formation of Neutrophil-Derived Extracellular Traps (NETosis) and Uses ThereofBRIGHAM & WOMENS HOSPITAL INC·Filed 2022·Application pending·0 cites
- 4054US2011200686A1Compositions of modulators of the wnt/b-catenin pathway and an n-cinnamyl-n'benzhydryl piperazine and their use in treating neoplastic conditions including malignant melanomaUNIV OG WASHINGTON·Filed 2009·Application pending·0 cites
- 4154US2024285777A1Inhibitors of ttbk1MASSACHUSETTS GEN HOSPITAL·Filed 2022·Application pending·0 cites
- 4254US2023226195A1Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an e3-ligase systemDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 4354US2012039909A1Epigenetic mechanisms re-establish access to long-term memory after neuronal lossTSAI LI-HUEI·Filed 2011·Application pending·0 cites
- 4454US2015190411A1Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survivalMASSACHUSETTS INST TECHNOLOGY·Filed 2014·Application pending·0 cites
- 4554US2011251144A1Molecular modulators of the wnt/beta-catenin pathwayMASSACHUSETTS INST TECHNOLOGY·Filed 2009·Application pending·0 cites
- 4652US2010292209A1Methods for identifying compounds that modulate neurotrophic factor signalingMASSACHUSETTS INST TECHNOLOGY·Filed 2008·Application pending·0 cites
- 4752US2012101147A1Inhibition of hdac2 to promote memoryTSAI LI-HUEI·Filed 2009·Application pending·0 cites
- 4851US2013039998A1Compositions of modulators of the wnt/beta-catenin pathway and benzamide and/or hydroxamic acid derivatives to treat bipolar disorderUNIV WASHINGTON·Filed 2009·Application pending·0 cites
- 4951US2023133538A1Targeted degraders of aberrant tau based on the pet tracer pbb3DANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 5050US8841346B2Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disordersTSAI LI-HUEI·Filed 2012·Granted Sep 23, 2014·0 cites·16 claims
Showing the top 50 of 55 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →